Bifurcations Bad Krozingen I

Similar documents
LM stenting - Cypher

FFR-guided Jailed Side Branch Intervention

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Insight from Nordic III

A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations

PROMUS Element Experience In AMC

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

Y. Louvard, ICPS, Massy, France. TCT Asia Pacific 2010

ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Non-LM bifurcation studies of importance in 2011

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

The Nordic Bifurcation Stent Technique Study. A Randomized trial of CRUSH vs CULOTTE Stenting

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators

Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial

Stent Thrombosis in Bifurcation Stenting

Unprotected LM intervention

Contemporary therapy of bifurcation lesions

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

Insight from the CACTUS trial Coronary Bifurcation Application of the Crush

Provisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB

DESolve NX Trial Clinical and Imaging Results

Lessons learned From The National PCI Registry

The Japanese Pharmacokinetic (PK) Study of Sirolimus-Coated Bx VELOCITY Balloon-Expandable Stent in Patients With de novo Coronary Artery Lesions

Final Kissing Ballooning Returns? The analysis of COBIS II registry

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester

PCI for Left Anterior Descending Artery Ostial Stenosis

New Generation Drug- Eluting Stent in Korea

Prevention of Coronary Stent Thrombosis and Restenosis

Welcome to the 8 th European Bifurcation Club October Barcelona

Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe

Percutaneous Intervention of Unprotected Left Main Disease

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Abstract Background: Methods: Results: Conclusions:

C. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller

PCI for Long Coronary Lesion

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL

Bifurcation stenting with BVS

Drug Eluting Stents: Bifurcation and Left Main Approach

Update from the Tryton IDE study

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France

TCT mdbuyline.com Clinical Trial Results Summary

The MAIN-COMPARE Study

Bifurcation Stenting: IVUS and OCT Information

Complex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ".

Biodegradable Stents An update and work-in

Clinical Investigations

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

Why I try to avoid side branch dilatation

Long-term outcomes of simple crossover stenting from the left main to the left anterior descending coronary artery

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

Perspective of LM stenting with Current registry and Randomized Clinical Data

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Tailored bifurcation therapy

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries

Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions

PCI for Chronic Total Occlusions

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD

Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention

Protection of side branch is essential in treating bifurcation lesions: overview

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

TRIAS HR Pilot Study

PCI for Bifurcation Coronary Lesion

The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

Inspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath

Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea

The SYNTAX-LE MANS Study

The tailored solution for your bifurcation therapy

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

In-Stent Restenosis. Can we kill it?

Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials

Count Down to COMBAT

Complex Coronary Interventions: Bifurcations. John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

Lesions at coronary bifurcations represent a challenging

Biosensors Lunch Symposium

Moins de 6 mois d antiagrégants après DES?

eluting Stents The SPIRIT Trials

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study.

Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance

FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Transcription:

Bifurcations Bad Krozingen I Clinical outcome 5 years after routine T-Stenting versus provisional T-stenting in the treatment of de novo coronary bifurcation lesions using sirolimus-eluting stents M. Ferenc

Background Previous studies demonstrated no benefit of systematic double stenting compared with single stenting in de-novo coronary bifurcation lesions (NORDIC; BBK I; BBC;) during short follow-up There is a lack of complete long term follow-up comparing single and double stenting

Objective We analysed the long term follow-up after percutaneus treatment of coronary bifurcation lesions with sirolimus-eluting stents (CYPHER) routine T-stenting of both main and the side branch reduces the restenosis in the side branch compared with provisional T-stenting.

Patient selection Inclusion criteria Stable angina pectoris and/or posi2ve stress test De novo bifurcated lesion of a na2ve coronary artery Reference vessel diameter of 2.5 to 4.0 mm in the main branch and of 2.25 mm in the side branch > 50% diameter stenosis of main branch and/or side branch Exclusion criteria Acute myocardial infarc2on within 72 hours Contraindica2on to aspirin, heparin, clopidogrel, stainless steel, sirolimus History of bleeding diathesis or coagulopathy Intraluminal thrombus, heavy calcifica2on and/or severe tortuosity

Prospective randomized study April 2005 August 2006 202 patients with de novo bifurcation lesion Provisional T-stenting n = 101 Systematic T-stenting n = 101 Angiographic follow-up with QCA at 9 months ( Medis bifurcation program) Primary endpoint In-segment percent diameter stenosis of the side branch at angiographic follow-up Clinical follow-up at 1,2 and 5 years

Provisional T- sten2ng Technical approach Rou2ne modified T- sten2ng Stent placement in the main branch

Provisional T- sten2ng Technical approach Rou2ne modified T- sten2ng Final kissing balloon dilata2on

Provisional T- sten2ng Technical approach Rou2ne modified T- sten2ng Final kissing balloon dilata2on

Provisional T- sten2ng Technical approach Rou2ne modified T- sten2ng

Baseline demographics Provisional T-Stenting n = 101 Routine T-Stenting n = 101 p- Value Age (yrs) 66.7 ± 9.2 66.5 ± 10.5 0.915 Male sex (%) 79.2 78.2 0.500 Previous MI (%) 18.8 20.8 0.430 History of PCI (%) 44.6 51.5 0.199 2 or 3-vessel disease (%) 65.3 74.2 0.457 History of CABG (%) 4.0 3.0 0.500 Ejection fraction (%) 59.1 60.8 0.297 Diabetes (%) 25.7 18.8 0.155

Distribution of Medina classification 35% 111 5% 6% p=0.906 12% 001 001 010 31% 111 010 14% 011 25% 110 011 110 31% 100 101 10% 101 100 12% 2% 3% 8% 6% True bifurcation = 68 % True bifurcation = 68 % Provisional T-Stenting Systematic T-Stenting

Procedural data Provisional T-Stenting n = 101 Systematic T-Stenting n = 101 p- Value Cross-over (%) 18.8 3.0 <0.001 Final kissing balloon (%) 100 100 n.s.

Cumula2ve distribu2on (%) 100 90 80 70 60 50 40 30 20 10 0 9.4 % Ferenc et al., Eur Heart J 2008 The BBK I - Study: 202 pa2ents - SES - Angiographic Primary Endpoint - 12.5 % P = 0.15 Provisional T- Sten2ng Rou2ne T- Sten2ng 0 10 20 30 40 50 60 70 80 90 100 Percent diameter stenosis of the side branch

BBK I - TLR 5 years post index-pci 20 Cumulative incidence (%) 15 10 5 0 P = 0.97 Provisional T-stenting Routine T-stenting 16.3 % 16.2 % 0 1 2 3 4 5 Years after PCI

BBK I - MACE 5 years post index-pci Cumulative incidence (%) 25 20 15 10 5 0 P = 0.91 Provisional T-stenting Routine T-stenting 22.9 % 22.8 % 0 1 2 3 4 5 Years after PCI

BBK I - Death / MI 5 years post index-pci 20 Cumulative incidence (%) 15 10 5 0 P = 0.40 Provisional T-stenting Routine T-stenting 13.9 % 9.9 % 0 1 2 3 4 5 Years after PCI

BBK I - Death 5 years post index-pci 10 10.0 % Cumulative incidence (%) 8 6 4 2 0 P = 0.65 Provisional T-stenting Routine T-stenting 7.9 % 0 1 2 3 4 5 Years after PCI

BBK I - probable/definite stent thrombosis 5 years post index-pci Cumulative incidence (%) 10 8 6 4 2 Inten2on- to- treat cohort: Rou2ne T- sten2ng Provisional T- sten2ng P=0.25 0 0 1 2 3 4 5 Years a_er PCI

BBK I - probable/definite stent thrombosis 5 years post index-pci Cumulative incidence (%) 10 8 6 4 2 Inten2on- to- treat cohort: Rou2ne T- sten2ng Provisional T- sten2ng As- treated cohort: Double sten2ng Single sten2ng 6.1 % P=0.25 P=0.02 0 0 % 0 1 2 3 4 5 Years a_er PCI

BBK I study - Clinical outcome 5 years post PCI - Analysis as treated - Single T-Stenting Double T-Stenting n=85 n=117 TLR (%) 12.0 19.4 0.16 Any MACE (%) 18.9 25.7 0.26 Death (%) 7.1 10.3 0.44 Death and/or MI (%) 9.4 13.7 0.35 Stent thrombosis (def/prob) (%) 0 6.1 0.02 p

Conclusions During 5-year follow-up, routine T-stenting offered no advantage over provisional T-stenting with respect to TLR or MACE. Double stenting compared with single stenting was associated with an increased 5-year risk of stent thrombosis.